Area of research
Hematology · Pediatrics, Perinatology and Child Health
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Childhood Cancer Survivors' Quality of Life, Acute Lymphoblastic Leukemia research, and Pediatric Pain Management Techniques.
Distinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation
Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity
Identification of Distinct Subtypes in Immune Tolerance after Hematopoietic Cell Transplantation Using the Prospective ABLE1.0 Pediatric Study Cohort
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231
A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
A Day 14 Endpoint for Acute GVHD Clinical Trials
Impact of dexamethasone on transplant-related mortality in pediatric patients: a multi-site, propensity score–weighted, retrospective assessment
The Mount Sinai Acute Gvhd International Consortium (MAGIC) Model: An Integrated Clinical and Biomarker Grading System for Acute Graft-Versus-Host Disease (GVHD)
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
A diagnostic classifier for pediatric chronic graft-versus-host disease: results of the ABLE/PBMTC 1202 study
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)
Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease
Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies
Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease
Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria
Comparison of Gvhd Biomarker Algorithms for Predicting Lethal Gvhd and Non-Relapse Mortality
Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report
A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium
Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report